Peter S. Kaplan: Building Breakthrough Companies One Aligned Leader at a Time
Photo Courtesy: Peter S. Kaplan

Peter S. Kaplan: Building Breakthrough Companies One Aligned Leader at a Time

By Natalie Johnson

Most early-stage life sciences failures get written up as science failures. The molecule did not work, the trial read out badly, the device did not clear. That story is tidy and often wrong. Long before the data arrives, a leadership team has already decided what to prove, what to spend, what to skip, and who owns the call. If those decisions were made by executives holding four different definitions of success, the company burned through valuable capital on the wrong experiments and found out months later. Peter S. Kaplan, Founder and President of Synergy Search Partners LLC, treats that failure as the one boards can control, and he argues it starts with a word most directors use loosely: alignment.

Alignment Is Not Agreement

The common misreading is that an aligned leadership team is a harmonious one. Kaplan’s definition cuts the opposite way. “A well-aligned leadership team should challenge one another vigorously,” he says. “Alignment means that disagreement improves the decision rather than fragments the organization.” Leaders can argue hard over a development strategy or a financing path and still walk out committed to the same priorities, accountabilities, and standards. The failure mode is not conflict. It is conflict that leaks out of the room and turns into functions quietly pursuing different plans.

He breaks the alignment problem into four dimensions, and each one maps to a specific way early-stage companies lose money. Scientific and patient purpose asks what problem is being solved and what evidence would prove the approach matters. Strategy and capital asks what must be proven next, what it will cost, and what the company will deliberately not pursue. That second half is the part teams skip. Execution asks who owns each critical decision and how functions work together. Values and behavior asks how the organization handles uncertainty, disappointing data, difficult trade-offs, and dissent. A team that has never discussed the fourth dimension will discover its answer in the worst possible week, when a readout disappoints, and nobody knows whether candor is rewarded or punished.

What A Résumé Cannot Tell A Board

Early-stage executive hiring relies on the wrong signals. Candidates are screened on where they have been, and proximity to a successful company gets treated as a predictor. Kaplan rejects the logic outright. “A strong résumé tells me what someone has been near,” he says. “It does not necessarily tell me what they built, which decisions they owned, or whether they can repeat that success with fewer resources.” The question he wants asked is not whether a candidate worked at a winner, but how their leadership contributed to the win. That reframing eliminates a large share of impressive-looking shortlists.

His assessment runs across five qualities, and they are harder to fake than a logo:

  1. Hands-on judgment: Can the executive operate without the infrastructure that a larger organization provided, with specific examples of what they personally decided, built, or stopped?
  2. Learning agility: Can they describe a consequential assumption they changed, and name the evidence that changed their mind?
  3. Organizational strategy: Can they move from doing the work to building the team, systems, and decision processes that let others do it?
  4. Enterprise thinking: Can they connect functional choices to clinical value, capital requirements, regulatory strategy, and broader objectives?
  5. Talent multiplication: Do they hire people who extend the organization’s capabilities, delegate real authority, and develop successors?

The pattern across all five is evidence of behavior under constraint, which is precisely what venture-stage work supplies in abundance.

The same discipline applies to the familiar board debate over whether to hire for today or for the future. Kaplan challenges the premise that these must be two different people, or that one leader should carry every stage. The real gap is a vague mandate. “We need a world-class CEO” is not a mandate. “We need someone who can deliver the next clinical milestone, finance the company through it, and establish credible strategic options” is much closer. Boards should separate an executive’s development needs from the capabilities the organization must have immediately. Some gaps close with a complementary hire, an experienced chair, or a well-defined advisory relationship. Others sit at the center of the mandate and cannot responsibly be deferred. His counsel: hire for the next meaningful chapter, assess capacity to grow beyond it, and treat succession as ongoing governance rather than a verdict delivered after something breaks.

What Boards Will Be Buying Next

AI fluency has become a line item in executive specifications, usually without anyone defining it. Kaplan separates fluency from technical expertise. Not every life science executive needs to build an AI model. They do need to understand where AI can improve decisions, what evidence supports its use, and where people remain clearly responsible. He translates that into three testable capabilities:

  1. Business judgment: meaning the ability to identify a valuable use case rather than start with a technology hunting for a problem.
  2. Governance judgment: meaning clear ownership for data use, confidentiality, oversight, and escalation.
  3. Change leadership: meaning the ability to redesign workflows, develop people, and measure whether adoption improves performance.

Looking two to three years out, he expects boards to value leaders who integrate disciplines, preserve strategic options, and deliver measurable progress. Capital allocation and business development will sit closer to strategy, with demand for chief executive officers, chief financial officers, and business-development leaders who can weigh financing, licensing, partnerships, and acquisition pathways together, and who understand how each choice changes the company’s future. Commercial and access judgment will be asked about earlier, before a company is commercial. That does not require a full commercial organization at the seed stage. It requires someone at the leadership table connecting evidence generation to the needs of future customers, partners, and payers. He also expects demand for leaders who can read shifting competitive, regulatory, and geopolitical conditions without letting uncertainty freeze execution, noting that current biopharma leadership research identifies policy and geopolitics, China’s expanding innovation ecosystem, and global competitive dynamics as chief executive-level considerations.

Board composition deserves the same rigor as executive composition. Kaplan’s test for every director seat is direct: what judgment will this person contribute that the board does not already have. Prominent names fail that test routinely. Breakthrough companies, in his view, need leaders aligned on purpose, honest about evidence, disciplined about capital, and willing to evolve. That is why he treats search as something other than filling a seat. “The goal is to understand the company’s next consequential decisions and identify the leader whose judgment, capabilities, and behavior will help the entire organization succeed and make them better.”

Follow Peter S. Kaplan on LinkedIn for more insights on life sciences leadership, executive assessment, and board composition.

This article features branded content from a third party. Opinions in this article do not reflect the opinions and beliefs of New York Weekly.